Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study Cover

.blurhash-client-img { display: none !important; }

Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study

Radiology and Oncology

Volume 58 (2024): Issue 3 (September 2024)

By: Nezka Hribernik, Katja Strasek, Daniel T Huff, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj and Martina Rebersek

Open Access

|Sep 2024

Metrics

DOI: https://doi.org/10.2478/raon-2024-0045 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 335 - 347

Submitted on: Jun 13, 2024

Accepted on: Jul 14, 2024

Published on: Sep 15, 2024

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

¹⁸F-FDG PET/CT,

immune-checkpoint inhibitors,

immune-related adverse effects,

quantitative imaging biomarkers,

SUV percentiles

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2024 Nezka Hribernik, Katja Strasek, Daniel T Huff, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous article Volume 58 (2024): Issue 3 (September 2024)Next article